Fig. 1From: Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trialEffect of empagliflozin on estimated fluid volume status through week 24. eEV estimated extracellular volume, eGD estimated group difference, ePV estimated plasma volumeBack to article page